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 Although surgical and endovascular
revascularization can be performed in
patients with peripheral arterial disease
(PAD), 40% of patients with critical limb
ischemia do not have a revascularization
option.
 The efficacy of an injectable tissue-specific
skeletal muscle extracellular matrix (ECM)
hydrogel and a human umbilical cord-derived
ECM hydrogel were examined in a rodent
hindlimb ischemia model.
 Although both biomaterials increased
tissue perfusion 35 days post-injection,
likely through arteriogenesis, the skeletal
muscle ECM hydrogel more closely
matched healthy tissue morphology.
 Transcriptomic analysis indicates the
skeletal muscle ECM hydrogel shifted
the inflammatory response, decreased
necrosis/apoptosis, and increased blood
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33SUMMARYAlthough surgical and endovascular revascularization can be performed in peripheral arterial disease
(PAD), 40% of patients with critical limb ischemia do not have a revascularization option. This study
examines the efficacy and mechanisms of action of acellular extracellular matrix-based hydrogels as a
potential novel therapy for treating PAD. We tested the efficacy of using a tissue-specific injectable
hydrogel derived from decellularized porcine skeletal muscle (SKM) and compared this to a new human
umbilical cord-derived matrix (hUC) hydrogel, which could have greater potential for tissue regeneration
because of the younger age of the tissue source. In a rodent hindlimb ischemia model, both hydrogels
were injected 1-week post-surgery and perfusion was regularly monitored with laser speckle contrast
analysis to 35 days post-injection. There were significant improvements in hindlimb tissue perfusion and
perfusion kinetics with both biomaterials. Histologic analysis indicated that the injected hydrogels were
biocompatible, and resulted in arteriogenesis, rather than angiogenesis, as well as improved recruitment
of skeletal muscle progenitors. Skeletal muscle fiber morphology analysis indicated that the muscle
treated with the tissue-specific SKM hydrogel more closely matched healthy tissue morphology. Whole
transcriptome analysis indicated that the SKM hydrogel caused a shift in the inflammatory response,
decreased cell death, and increased blood vessel and muscle development. These results show the
efficacy of an injectable ECM hydrogel alone as a potential therapy for treating patients with PAD.
Our results indicate that the SKM hydrogel improved functional outcomes through stimulation of
arteriogenesis and muscle progenitor cell recruitment. (J Am Coll Cardiol Basic Trans Sci 2016;1:
32–44) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology
Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).SEE PAGE 45
AB BR E V I A T I O N S
AND ACRONYM S
CLI = critical limb ischemia
ECM = extracellular matrix
hUC = human umbilical cord
matrix
LASCA = laser speckle
contrast analysis
PAD = peripheral artery
disease
SKM = skeletal muscle matrixM ore than 27 million patients in NorthAmerica and Europe have been diag-nosed with peripheral artery disease
(PAD) (1). This disease leads to an estimated
120,000 patients in the United States and 100,000
patients in Europe requiring lower extremity
amputations annually due to decreased limb perfusion
(2). Surgical and endovascular revascularization (3)
is frequently performed, but 40% of patients
with critical limb ischemia (CLI) do not have a
revascularization option due to extreme tissue
damage and/or diffuse atherosclerotic disease
(4,5). There is also a high rate of post-
revascularization amputation and therefore a need
to develop new tissue salvage therapy for these
patients exists (6).
Minimally invasive, injectable therapies have
been investigated as a promising option for treat-
ing patients with PAD. Potential therapies that
utilize cells, growth factors, or gene therapies are
currently in clinical trials with the goal of
increasing perfusion in the ischemic limbs (7,8).
Cell therapy has however been plagued by poor
cell retention and survival, as well as the viability
and expense issues surrounding a living product.
Growth factor therapies have suffered from poor
retention of therapeutic proteins in the tissue, andgene delivery results have not translated to clinical
benefit (9). While injectable biomaterial alone ap-
proaches have been explored to treat ischemic cardiac
muscle (10,11), they have not been extensively
explored for treating the ischemic skeletal muscle
associated with PAD. When designed appropriately,
injectable biomaterials can be employed to create new
scaffolds that recruit endogenous cells to repair
damaged tissue.Our group previously developed an injectable
hydrogel derived from decellularized porcine
skeletal muscle extracellular matrix (SKM) (12).
Preliminary histological analysis within the
local region of the injected biomaterial in a
mild rodent hindlimb ischemia model sug-
gested that this acellular approach has the
potential to not only stimulate vessel
growth, but also could aid in treating
the muscle atrophy associated with PAD
(12). However, the global effect on neo-
vascularization and muscle remodeling, as
well as functional perfusion, which is a
mainstay of translational studies for PAD,
were not assessed. In the present study we
FIGURE 1 Functional Perfusion Study Design in a Rat Hindlimb Ischemia Model
(A) In vivo study timeline. (B) Hindlimb perfusion measured with laser speckle contrast analysis (LASCA). Image is post-surgery with
a significant decrease in perfusion of the ischemic (right) limb compared to the healthy (left) limb. (C) Example perfusion measurement
for a single ischemic animal. Healthy limb (blue line), the ischemic limb (red line), and total body (black line) are plotted over
time in arbitrary units or perfusion units. Perfusion kinetics ratio was calculated by dividing the slope of the linear region of the
healthy limb (blue dotted line) by the slope of the linear region of the ischemic limb (red dotted line). (D) Pre-surgery and
immediately post-surgery readings for each treatment group. Histo ¼ histology; Inj ¼ injection; IS ¼ ischemia surgery; PM ¼ perfusion
measurement.
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34investigated the tissue-specific SKM hydrogel com-
pared to a new non–tissue-specific hydrogel derived
from decellularized human umbilical cord matrix
(hUC) in a rodent hindlimb ischemia model with
chronically reduced perfusion to test their ability
to improve hindlimb tissue perfusion, neovas-
cularization, and muscle fiber remodeling.
MATERIALS AND METHODS
Full Methods are included in the Supplemental
Appendix. These include: ECM hydrogel develop-
ment and characterization, in vitro proliferation and
migration, hindlimb ischemia surgery and biomate-
rial injection, hindlimb functional perfusion mea-
surements, histological analysis, microarray analysis
and quantitative polymerase chain reaction, and
statistical analysis. All experiments in this study
were performed in accordance with the guidelines
established by the Institutional Animal Care and
Use Committee at the University of California, San
Diego, and the American Association for Accredita-
tion of Laboratory Animal Care. Briefly, unilateral
hindlimb ischemia was induced in female SpragueDawley rats by removing a 2 cm segment of the
femoral artery and vein. A biomaterial alone, SKM
(n ¼ 9) or hUC (n ¼ 10), or saline control (n ¼ 11)
was injected into the gracilis muscle distal from the
vessel ligation 7 days post-surgery. Ischemia was
confirmed and monitored with laser speckle
contrast analysis (LASCA) over 35 days post-
injection. SKM alone was compared to saline at 3
and 10 days post-injection with histology and whole
transcriptome analysis. Data are mean  SEM unless
otherwise noted. Significance was accepted at p <
0.05.
RESULTS
DECELLULARIZED TISSUES CAN BE PROCESSED INTO
INJECTABLE HYDROGELS AND DIFFERENTIALLY AFFECT
CELL MIGRATION AND PROLIFERATION IN VITRO. For
comparison to the porcine SKM hydrogel, we devel-
oped a new non–tissue-specific injectable biomaterial
from decellularized human umbilical cord tissue
(hUC). Biomaterial characterization, including quan-
titative mass spectrometry analysis (Supplemental
Figure 1, Supplemental Tables 1 to 4), and in vitro
FIGURE 2 Hindlimb Tissue Perfusion and Perfusion Kinetics
(A) Hindlimb perfusion measurements over the 42-day period for animals treated with either the skeletal muscle matrix (SKM) (n ¼ 9), human umbilical
cord matrix (hUC) (n ¼ 10) hydrogels, or saline (n ¼ 11). Readings are shown after the animal had been under anesthesia for 5 min, 10 min, and after
reaching perfusion equilibrium. Vertical dotted line indicates time of treatment injection on day 0. (B) Individual animal perfusion readings on day 35.
(C) Example representative perfusion images for each treatment group after the animal was under anesthesia for 10 min. Healthy limbs are on the left
and ischemic/treated limbs are on the right. Note: Because the units for perfusion are arbitrary, color comparisons cannot be performed between 2
different animals. (D) Perfusion kinetics for pre-surgery and post-surgery. (E) Pre-injection perfusion kinetics on day 2 (pre-injection). (F) Final
perfusion kinetics on day 35. A 2-way analysis of variance was conducted to compare within and between treatment groups. εp < 0.05 for SKM
compared to SKM at day 7 as determined by a Dunnett’s multiple comparisons test. *p < 0.05, **p < 0.01, and ***p < 0.001, and sp < 0.05 for both
treatment groups compared to saline using a Tukey post hoc test.
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FIGURE 3 Histological Assessment of Arteries and Capillaries
(A) Capillary density quantification. (B) There were no differences in arteriole density
between all groups, but (C) the average arteriole diameter (p ¼ 0.0389) and (D) density of
arterioles with diameter >75 mm (p ¼ 0.0344) was significantly increased in the skeletal
muscle matrix (SKM) group. Data from the healthy limb is shown as a reference. (E)
Representative image of capillaries stained by alkaline phosphatase for the SKM treatment
group. (F) Example arteriole staining with anti-aSMA (red) and nuclei (blue) for saline (n ¼
11), (G) SKM (n ¼ 9), and (H) human umbilical cord matrix (hUC) (n ¼ 10). *p < 0.05 and
scale bars are 100 mm.
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36effects on cell proliferation and migration
(Supplemental Figure 2) are described in the
Supplemental Appendix.
INJECTABLE ECM HYDROGELS INCREASE HINDLIMB
TISSUE PERFUSION. To mimic chronically reduced
perfusion associated with PAD, a rat hindlimbischemia model was utilized (Figure 1A). ECM
hydrogels or saline were injected 1 week after
ischemia induction (day 0), and tissue perfusion
was assessed utilizing LASCA (Figure 1B) (13).
LASCA allowed for continuous monitoring and
instantaneous full-field analysis of an animal with
readings lasting at least 20 min to reach perfusion
equilibrium (Figure 1C). Percent perfusion of the
ischemic limb to healthy limb was calculated once
the animal had been under anesthesia for 5 min, 10
min, and then after reaching perfusion equilibrium,
to allow for comparison to currently published laser
Doppler data, which is only analyzed at a single
time point post-anesthesia induction, typically
around 10 min (14,15). Both the pre- and immedi-
ately post-surgery perfusion measurements were
compared between treatments group and shown to
not be statistically different by a 2-way analysis of
variance (Figure 1D).
Both of the injected hydrogels alone, SKM or
hUC, led to a significant increase in percent
perfusion compared to saline as early as day 21
post-injection (Figure 2A) and this improvement
was maintained until the end of the study on day
35 (Figures 2B and 2C). For example, the day 35
measurements after being under anesthesia for 10
min (a typical time for laser Doppler measure-
ments) (14) showed the ischemic damaged limb to
be perfused at 65.7  13.3% for saline, 96.4 
13.8% for SKM (p < 0.001, compared to saline), and
84.2  14.3% for hUC (p < 0.05, compared to
saline). All 3 perfusion assessments, at 5 and 10
min under anesthesia and at equilibrium, showed
that saline animals plateaued 7 days post-injection;
subsequent measurements at days 14, 21, 28, and
35 were not statistically different than at day 7
(Figure 2A) (p > 0.05). Animals injected with hUC
hydrogel also did not significantly improve from
their perfusion at day 7 (Figure 2A) (p > 0.05). In
contrast, perfusion in SKM animals was signifi-
cantly higher at day 35 compared to day 7 at the
10-min reading, and at days 21, 28, and 35
compared to day 7 at equilibrium (Figure 2A)
(p < 0.05).
Due to the use of LASCA we were able to monitor
dynamic perfusion while the animals were under
anesthesia. The animals were initially anesthetized
with 5% isoflurane and then transferred to 2.5%
when the perfusion reading started. Decreasing the
level of isoflurane creates an increase in cardiac
output and blood perfusion in the peripheral skel-
etal muscle (16). Thus, the perfusion increased in
the hindlimbs as the animal rested on the deck, as
illustrated in Figure 1C. From this data, a new
FIGURE 4 Biocompatibility Assessment and Muscle Fiber Morphology Quantification
(A) Hematoxylin and eosin (H&E) stained transverse section showing healthy fiber morphology. (B) Macrophages were stained with CD68 as shown (black arrow).
(C) Extracellular matrix stained with a laminin antibody (green) and nuclei were counter stained (blue) for saline (n ¼ 11), human umbilical cord matrix (hUC) (n ¼ 10),
and skeletal muscle matrix (SKM) (n ¼ 9) treated animals. (D) Percent ECM was measured from laminin stained slides. (E) Percent of fibers with centrally located nuclei.
(F) Average fiber area. (G) Average fiber circularity. (H) Average fiber roundness. Scale bars are 100 mm and all images are representative from an SKM hydrogel treated
animal. *p < 0.05, **p < 0.01, ***p < 0.001, and ap < 0.001 compared to all other groups.
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37parameter called perfusion kinetics ratio can be
reported to show the rate of change of perfusion
over time. This was calculated as a ratio of the
slopes from the linear region of the perfusion
measurements (indicated by dotted lines on
Figure 1C) from the ischemic foot to the healthy foot.
Perfusion kinetics ratios that deviate from 1 thus
illustrate differences in perfusion between the 2 legs,
with values <1 demonstrating a slower response to
changes in cardiac output in the ischemic limb. The
healthy animals pre-surgery had symmetric perfu-
sion rates in each limb, or a perfusion kinetics ratio
near 1 (Figure 2D). Immediately post-surgery, the
ischemic damaged tissue showed a decreased rate
of change in perfusion, which is indicated by the
perfusion kinetics ratio being close to zero for all
groups (Figure 2D). By day 5 post-ischemia (2 days
pre-injection), the animals had partially recovered
due to endogenous healing mechanisms and pro-
duced consistently improved perfusion kinetics ra-
tios of approximately 0.4 (Figure 2E). Finally, by the
end of the study, perfusion kinetics ratios for the
SKM and hUC hydrogels showed significant im-
provements over the saline (p < 0.001 for SKM; p <0.01 for hUC) control, which was maintained at
approximately 0.4 (Figure 2F).
ECM HYDROGELS STIMULATED INCREASED DENSITY
OF LARGER ARTERIOLES. Capillary and arteriole den-
sities were analyzed on tissue cross-sections sampled
throughout the entire gracilis muscle at day 35.
Although average capillary (Figure 3A) and arteriole
density (Figure 3B) did not vary between treatment
groups, there was a significant increase in the average
arteriole diameter for SKM animals compared to sa-
line (Figure 3C). More specifically there was an in-
crease in the density of larger arterioles with a
diameter >75 mm (Figure 3D). Similar trends were
observed for the hUC hydrogel, but were not sta-
tistically significant compared to saline. A repre-
sentative image of capillary staining for the SKM
group is shown in Figure 3E, while example arteriole
staining from all treatment groups is shown in
Figures 3F to 3H.
HYDROGELS WERE FULLY DEGRADED WITHOUT A
CHRONIC INFLAMMATORY RESPONSE AND SKM
HYDROGEL PROMOTES MUSCLE REMODELING. On
FIGURE 5 Short-Term Histological Assessment of Arteries and Capillaries
Histological analysis taken at (A, C, E, G) day 3 and (B, D, F, H) day 10 post-injection. There
were no differences in (A, B) capillary density, (C, D) arteriole density, or (E, F) average
arteriole diameter between SKM and saline at these early timepoints, but (E,F) the density
of arterioles with diameter >75 mm trended higher in the SKM (n ¼ 6) group compared to
saline (n ¼ 6).
Ungerleider et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 1 - 2 , 2 0 1 6
Injectable ECM Hydrogel for Treating PAD J A N U A R Y / F E B R U A R Y 2 0 1 6 : 3 2 – 4 4
38day 35 post-injection, hindlimb muscle tissue cross
sections were stained with hematoxylin and eosin
and analyzed by a histopathologist blinded to the
treatment groups. Histological analysis concluded
that the biomaterials had fully degraded, and no
scarring or chronic inflammatory response was
observed. Macrophages in the tissue were very low
in density, seen as only single cells evenly spaced
throughout the tissue. Representative images from
the SKM group are shown in Figures 4A and 4B.
Next, laminin staining (Figure 4C) was utilized to
measure area fraction of ECM to assess interstitial
ECM deposition (17). No significant differences were
observed with about 20% of the surveyed area
being covered by positively stained laminin
(Figure 4D).
Fibers with centrally located nuclei can be an
indicator of abnormal fibers, representing damaged
or remodeling muscle (18). No significant differ-
ences in the percentage of fibers with centrally
located nuclei were observed by day 35, with an
average of about 2% of the fibers (Figure 4E). In-
dividual fiber morphology (cross-sectional area,
circularity, and roundness) was also measured and
the batched quantified fiber populations were
analyzed for animals treated with saline (7,946 fi-
bers), SKM hydrogel (8,302 fibers), and hUC hydro-
gel (6,000 fibers) compared to healthy tissue (9,130
fibers). The average fiber area of SKM hydrogel–
treated animals was not significantly different than
the healthy tissue (Figure 4F). In contrast, the
average fiber area of the hUC hydrogel group was
significantly higher than the SKM hydrogel (p <
0.001) and healthy tissue (p < 0.01), and saline was
significantly less than all groups (p < 0.001)
(Figure 4F). Next, fiber circularity (ratio of short axis
to long axis) and fiber roundness (roughness or
angularity) of the muscle fibers also showed SKM
was most similar to the healthy tissue (Figures 4G
and 4H).
SKM HYDROGEL IMPROVED PERFUSION AND MUSCLE
REMODELING THROUGH INCREASED DENSITY OF
LARGER ARTERIOLES AND RECRUITMENT OF SKELETAL
MUSCLE PROGENITORS. We next sought to analyze
the temporal changes following ECM hydrogel in-
jection. We chose to focus subsequent studies on
the tissue-specific SKM hydrogel as it had
improved muscle remodeling compared to the hUC
hydrogel and because its readily available tissue
sourcing would make it cheaper and easier to
manufacture as a clinical product. We performed
an additional hindlimb ischemia study, comparing
saline and SKM injections at 3 and 10 days
FIGURE 6 Short-Term Histological Assessment of Skeletal Muscle Progenitor Cells
(A) Representative image of Pax-7þ (red) and Hoechst 33342 (blue) costaining in skeletal muscle matrix (SKM)–injected gracilis muscle. Scale
bar is 50 mm and Pax-7þ nuclei are indicated by white arrows. There were significantly more Pax-7þ cells as a percentage of total nuclei in SKM
(n ¼ 6) versus saline (n ¼ 6) injected muscles at (B) day 3, but this returned to quiescent levels by (C) day 10. *p ¼ 0.0096. Data from the
healthy limb is shown as a reference.
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39post-injection (day 10 and day 17 post-surgery,
respectively). There were no significant differ-
ences in capillary density, arteriole density, or
arteriole diameter between saline and SKM treated
muscles at these early time points (Figures 5A to
5F). However, similar to the previous experiment
at day 35, density of arterioles >75 mm trended
higher in SKM injected animals at both 3 and 10
days post-injection (Figures 5G and 5H).
Due to improvements in muscle remodeling at day
35 post-injection, we analyzed tissue at day 3 and 10
post-injection for infiltration of skeletal muscle
progenitors. Pax-7 is a transcription factor involved
in early stage muscle lineage commitment in skeletal
muscle satellite cells (19). Analysis of percentage of
Pax-7 positive nuclei (Figure 6A) showed the impact
of SKM injection on the gracilis muscle near
the material. At day 3, SKM injected muscles had a
significantly higher percentage of Pax-7þ nuclei
compared to saline (Figure 6B) (p < 0.05), but by day
10 Pax-7þ nuclei dropped to more quiescent levels
(Figure 6C).
SKM HYDROGEL PROMOTES A PRO-REGENERATIVE
ENVIRONMENT. We further investigated the mech-
anism of action of the SKM hydrogel through whole
transcript array analysis. Using a false discovery
rate of q < 0.1, there were 561 significantly differ-
entially regulated genes between saline and SKM
in the gracilis at 3 days and 16 genes at 10 days
(Supplemental Table 5). At 3 days post-injection,
Ingenuity pathway analysis showed shifts in the
inflammatory response and lipid and carbohydratemetabolism, and increases in muscle development
and cell survival with SKM (Table 1). Furthermore,
there was down-regulation of genes related to cell
death, response to hypoxia, ECM and cytoskeletal
organization, and blood vessel development. At 10
days post-injection, there continued to be a shift in
the inflammatory response and down-regulation of
cell death as well as up-regulation of cell adhesion
and motility, ECM organization, blood vessel
development, and neural system development
pathways. Gene ontology analysis also showed
differences in many molecular functions and bio-
logical processes, such as binding (GO:0005488),
catalytic activity (GO:0003824), metabolic process
(GO:0008152), developmental process (GO:0032502),
and immune system process (GO:0002376), be-
tween groups at both time points (Supplemental
Figures 6 to 9). Microarray analysis was validated
with quantitative polymerase chain reaction of
key genes (Supplemental Figure 3, Supplemental
Table 10).DISCUSSION
Various neovascularization therapeutic approaches
including cells, growth factors, and gene therapies
have been explored, but have been met with mixed
results in clinical trials for treating patients with
CLI associated with PAD (20). A biomaterial only
therapeutic approach could have several advantages
compared to the existing paradigm including off-the-
shelf availability, reduced cost, and the ability to
TABLE 1 Significantly Altered Pathways in SKM Relative to Saline Injected Muscle at 3 and 10 Days Post-Injection, as Determined by
Ingenuity Pathway Analysis
Category Annotation p Value z-score # Molecules
Day 3 up-regulated pathways
Lipid metabolism, small molecule biochemistry Conversion of lipid 0.0112 1.387 5
Cellular development, cellular growth and proliferation,
hematological system development and function
Proliferation of lymphocytes 0.0027 1.381 9
Cell death and survival Cell survival 0.0272 0.96 21
Cellular compromise, inflammatory response Degranulation of leukocyte cell lines <0.001 0.748 8
Cell morphology, cellular function and maintenance Transmembrane potential of mitochondria 0.0021 0.706 9
Cell signaling, molecular transport, vitamin and mineral
metabolism
Quantity of Ca2þ 0.0396 0.699 16
Carbohydrate metabolism Uptake of monosaccharide 0.0233 0.653 8
Cellular function and maintenance Endocytosis 0.0075 0.555 11
Cellular development, cellular growth and proliferation,
organ development, skeletal and muscular system
development and function, tissue development
Proliferation of muscle cells <0.001 0.486 22
Cell morphology, skeletal and muscular system
development and function
Contractility of muscle cells 0.0115 0.305 4
Day 3 down-regulated pathways
Cell-to-cell signaling and interaction Activation of cells 0.0161 –2.919 15
Cell death and survival Necrosis 0.0139 –2.126 58
Cell signaling, post-translational modification Tyrosine phosphorylation of protein 0.0401 –2 4
Cell death and survival Neuronal cell death 0.0011 –1.949 36
Cardiovascular system development and function,
organismal development
Vasculogenesis 0.0029 –1.604 15
Cell death and survival Apoptosis <0.0001 –1.484 75
Cellular movement Cell movement <0.001 –1.39 43
Cell Signaling, molecular transport, small molecule
biochemistry, vitamin and mineral metabolism
Release of Ca2þ 0.0486 –1.154 6
Cardiovascular system development and function,
organismal development
Angiogenesis 0.0050 –1.107 19
Cellular assembly and organization, cellular function
and maintenance
Organization of cytoskeleton 0.0127 –0.905 45
Day 10 up-regulated pathways
Cellular movement Cell movement 0.0089 1.709 7
Cellular movement Migration of cells 0.0453 1.455 5
Cardiovascular system development and function,
organismal development
Vasculogenesis 0.0037 1 4
Cellular growth and proliferation Proliferation of cells <0.00001 0.986 20
Inflammatory response Inflammatory response 0.0125 0.447 5
Cell morphology, cellular assembly and organization,
cellular development, cellular growth and
proliferation, nervous system development and
function, tissue development
Outgrowth of neurites <0.001 0.447 6
Cardiovascular system development and function,
organismal development
Angiogenesis 0.0023 0.277 5
Day 10 down-regulated pathways
Cell death and survival Cell death <0.001 –0.977 15
Cell death and survival Apoptosis 0.0050 –0.594 11
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40stimulate endogenous cell recruitment over multiple
days or weeks. In this study, we demonstrate the first
functional analysis of an injectable ECM-based
hydrogel for treating PAD by showing increased
perfusion in a hindlimb ischemia model and evidence
for improvement of the underlying muscle pathology.
We also present one of the first studies to investigate
the mechanisms of action behind decellularizedinjectable hydrogels through an unbiased whole
transcriptome analysis.
In this study, we used a newer imaging modality,
LASCA, to assess perfusion in the feet, which
allowed for instantaneous and continuous moni-
toring of the perfusion in the limbs. This provided
insight into the change in perfusion over time. For
comparison to previous publications that used laser
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41Doppler technology, which can only take a static
snapshot at a given time point (14,15), typically
within 10 min, we reported perfusion measurements
at 3 distinct time intervals after the onset of
anesthesia. At all 3 readings, the ECM hydrogels
significantly increased perfusion over the saline
control. In analyzing the equilibrium measure-
ments, which showed the least animal-to-animal
variability, perfusion increased over 3 weeks and
plateaued at day 21, which corresponds with the
material degradation time of approximately 3
weeks (12). The increases persisted out to day 35
post-injection. By using LASCA, we were also able
to characterize the dynamic perfusion changes un-
der anesthesia through calculation of the perfusion
kinetics ratio. This new measurement provides
insight into the health of the vascular network and
its ability to transition through a change in cardiac
output. By day 35, only the biomaterial treated
groups had perfusion kinetics ratios return to 1,
indicating the vessel network in the ischemic limb
was able to respond to changes in cardiac output at
the same rate as the healthy limb. This is clinically
relevant because patients with PAD and CLI have
shown a decreased or slowed rate of perfusion in
transition from states of lower perfusion to higher
perfusion. The decreased rate of change of perfu-
sion is associated with decreased vessel health and
compliance in diseased patients (21,22). The in-
crease in perfusion and restoration of hindlimb
perfusion kinetics directly correlated with histo-
logical quantification, which showed an increased
density of arterioles with diameters >75 mm
throughout the whole muscle, suggesting that the
biomaterial therapy acts via promoting arterio-
genesis rather than angiogenesis because capillary
density was not increased at any of the investi-
gated time points. Other studies have indicated
that a therapy impacting arteriogenesis rather than
angiogenesis may be more desirable for CLI pa-
tients (23,24).
While several in vitro studies have shown the
importance of ECM tissue specificity (25–29), limited
studies have examined whether tissue specificity is
necessary in vivo. In this study, we tested 2 different
ECM-derived hydrogels, which were both biocom-
patible. The SKM hydrogel represents a tissue-specific
ECM approach for treating skeletal muscle. For
comparison, a new injectable hydrogel derived from
human umbilical cords was developed as a non–
tissue-specific approach and as an ECM source with
potential for increased regeneration due to its young
age. In vitro, we show differences in the 2 tissuesources with respect to their effects on cell pro-
liferation and migration, but in vivo, while
some perfusion measures showed trends toward an
increase with SKM, both materials were capable of
significantly enhancing perfusion over the saline
control. Decellularized ECMs, including those from
xenogeneic sources and those processed into
hydrogels, have been shown to promote tissue
remodeling and healing in a variety of applications
(12,30–32). This positive tissue remodeling has
been attributed to a shift toward a pro-remodeling
immune response associated with Th2 lymphocytes
and M2 macrophages (33,34). Since we observed
an increase in perfusion with both materials this
could have been caused by this shift toward a
more pro-remodeling vs. pro-inflammatory response,
and suggests that non–tissue-specific responses
such as vascularization may be possible with non–
tissue-specific ECM. However, when we examined
measures of skeletal muscle remodeling post-
ischemic injury, we found that the SKM hydrogel
treated animals most closely matched the
morphology of healthy skeletal muscle and were
significantly different than the hUC hydrogel treated
animals. While the 2 ECM hydrogels are derived
from different species, they are both xenogeneic in
this model. In addition, given the different gelation
characteristics, there are likely small differences in
the mechanical properties between the 2 gels.
However, several studies have shown tissue-specific
responses with decellularized ECM in vitro (25–28),
many of which used 2D coatings where only the
biochemical cues and not the mechanical properties
were different. Taken together with our in vivo
results, this suggests that tissue specificity of the
material may be important for overall tissue
remodeling and regeneration. We show through a
targeted ECM proteomics approach that SKM and
hUC do have distinct ECM component signatures
despite being predominantly composed of collagen I.
This may be important for muscle regeneration,
given evidence in the literature correlating differ-
ential ECM composition with human myoblast pro-
liferation (35). When we examined the ischemic
muscle shortly after injection of the SKM hydrogel,
we found an increase in Pax-7þ skeletal muscle
progenitor cells. Pax-7 is up-regulated in regenerat-
ing muscle, but usually is expressed in about 5% of
nuclei in quiescent muscle (19). This suggests that
the SKM hydrogel is causing early stimulation of
muscle regeneration through recruitment of satellite
cells within the first week of material injection,
which may have resulted in the improved measures
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injection.
Due to the improvements in muscle remodeling,
as well as the improved translational outlook of
SKM over hUC because of the ease, cost, and
reduced variability with a porcine tissue source, we
chose to further investigate dynamic changes in
the global transcriptome due to SKM hydrogel in-
jection. Although microarray analysis has previ-
ously been employed to characterize the pre-
clinical hindlimb ischemia model (36,37) and hu-
man PAD patients (38), no studies have investi-
gated the effect of therapeutic interventions using
this global unbiased analysis. At day 3, compari-
sons between SKM and saline controls showed that
the SKM hydrogel promoted cell survival pathways,
immune response, and muscle proliferation and
contractility, while at day 10 the up-regulated
pathways shifted emphasis to vascular develop-
ment, neuron outgrowth, and cell motility. Genes
associated with extracellular matrix (ECM) were
down-regulated at day 3 but became up-regulated
at day 10. This correlates with other studies of
transcriptomic effects of skeletal muscle regenera-
tion, which show that ECM being up-regulated
at later time points is associated with tissue
repair, cell migration, and myogenic development
(39). Interestingly, apoptosis and response to hyp-
oxia were strongly down-regulated at both time
points, suggesting a pro-survival and regenerative
response of the SKM material compared to the
saline control across the entire muscle. These re-
sults suggest that the SKM hydrogel produces
functional outcomes through altering key pathways
associated with inflammatory response, cell death
and survival, metabolism, and vessel and muscle
development.
STUDY LIMITATIONS. Limitations of this study are
due to the inherent weaknesses of hindlimb
ischemia preclinical models for modeling PAD and
CLI. Unfortunately, no preclinical model fully
mimics all aspects of PAD or CLI. In particular, all
hindlimb ischemia models are acute models, while
PAD is a chronic condition (40). The standard
models for PAD and CLI are rodent models, which
due to young age and healthy collateral architec-
ture often heal to a great extent without
any therapeutic interventions (40,41). Even large
animal models and other rodent models that
mimic aspects of the patient population, such as
hyperhomocysteinemia, diabetes, hypercholester-
olemia, and/or aging, still show collateral vesselformation (40). To partially address these limita-
tions, we selected a vessel ligation and excision
protocol, which resulted in chronically reduced
perfusion (w65%) and muscle atrophy (reduced
muscle fiber cross-sectional area). While our model
did not have accompanying necrosis of the toes or
feet, it permitted us to inject the biomaterials 7
days post-ischemic injury to allow the acute
response from the surgery to resolve prior to
treatment. The small scale is another limitation of
these animal models. Here we delivered a single
bolus into the ischemic damaged region, whereas
in human patients multiple injections would be
utilized.
CONCLUSIONS
We have shown the efficacy of an injectable
biomaterial alone (SKM or hUC) to increase tissue
perfusion in a rat hindlimb ischemia study. Sig-
nificant differences in muscle remodeling at a
chronic time point indicate that utilizing a tissue-
specific biomaterial therapy for PAD may be
more desirable. Furthermore, improved arterio-
genesis and skeletal muscle progenitor cell
recruitment at shorter time points and gene ex-
pression differences related to inflammatory
response, blood vessel and muscle tissue develop-
ment, apoptosis, cell survival, and metabolism
give evidence of a transcriptome-wide improve-
ment in tissue regeneration due to the SKM
hydrogel.
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PERSPECTIVES
COMPENTENCY IN MEDICAL KNOWLEDGE: In a rat
model, injection of naturally derived ECM hydrogels
improved perfusion to the ischemic hindlimb. This is
the first pre-clinical study to specifically investigate
the effect of ECM hydrogels on functional perfusion in
hindlimb ischemia models.
TRANSLATIONAL OUTLOOK 1: Satisfaction of current
Good Manufacturing Practice regulations and additional
toxicology studies will be required prior to translation;
however, this functional study combined with the current
clinical use of porcine derived decellularized ECM and
initiation of a clinical trial with a similar cardiac ECM
derived hydrogel (NCT02305602) provides support for
the advancement of the SKM hydrogel into clinical trials
for treating patients with advanced PAD.
TRANSLATIONAL OUTLOOK 2: Considering this was
a small animal study with a single bolus injection, the
optimal number of injection sites and site locations would
need to be optimized for human patients. Also, the po-
tential exists for injecting a patient with the therapy
several times over numerous months, which was not
explored here.
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